Discovery Fueled by Ultra-Sensitivity Forward-Looking Statements & Non-GAAP Financial Measures 2 The Simoa advantages: ultra sensitivity that enables bloodbased detection in the earliest stages of disease, with a simplified workflow for scaled deployment. Alzheimer's Disease Continuum www.lucentdiagnostics.com Q2 2022 $23.5M $26.6M $25.8M CEO transition on April 25th Business strategic review starting in June $28.5M Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Strategic review completed in July, business ...